IN2014DN10691A - - Google Patents
Info
- Publication number
- IN2014DN10691A IN2014DN10691A IN10691DEN2014A IN2014DN10691A IN 2014DN10691 A IN2014DN10691 A IN 2014DN10691A IN 10691DEN2014 A IN10691DEN2014 A IN 10691DEN2014A IN 2014DN10691 A IN2014DN10691 A IN 2014DN10691A
- Authority
- IN
- India
- Prior art keywords
- metabolites
- propanamide
- benzofuranyl
- cyclopropyl
- dihydro
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 abstract 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649220P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/041573 WO2013173707A1 (en) | 2012-05-18 | 2013-05-17 | Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10691A true IN2014DN10691A (enExample) | 2015-08-28 |
Family
ID=48483244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10691DEN2014 IN2014DN10691A (enExample) | 2012-05-18 | 2013-05-17 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9212129B2 (enExample) |
| EP (1) | EP2855424B1 (enExample) |
| JP (1) | JP5959083B2 (enExample) |
| KR (3) | KR20150005691A (enExample) |
| CN (2) | CN104583178A (enExample) |
| AU (1) | AU2013262631B2 (enExample) |
| BR (1) | BR112014028446A2 (enExample) |
| CA (1) | CA2872324C (enExample) |
| CL (1) | CL2014003126A1 (enExample) |
| CO (1) | CO7151504A2 (enExample) |
| ES (1) | ES2648987T3 (enExample) |
| IL (1) | IL235485A (enExample) |
| IN (1) | IN2014DN10691A (enExample) |
| MX (1) | MX2014014010A (enExample) |
| NZ (1) | NZ701515A (enExample) |
| RU (1) | RU2632889C2 (enExample) |
| WO (1) | WO2013173707A1 (enExample) |
| ZA (1) | ZA201408014B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2806863T1 (sl) | 2012-01-26 | 2017-12-29 | Vanda Pharmaceuticals Inc. | Zdravljenje motenj cirkadianega ritma |
| AU2013262631B2 (en) | 2012-05-18 | 2016-02-04 | Vanda Pharmaceuticals Inc. | Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide |
| WO2015117048A1 (en) * | 2014-01-31 | 2015-08-06 | Vanda Pharmaceuticals Inc. | Treatment of circadian rhythm disorders |
| BR112021004214A2 (pt) * | 2018-09-12 | 2021-05-25 | Vanda Pharmaceuticals Inc. | método para aperfeiçoar o sono, desempenho pós-sono ou ambos, e, aperfeiçoamento em um método |
| WO2020138027A1 (ja) | 2018-12-25 | 2020-07-02 | 株式会社クボタ | 作業機 |
| MX2021009616A (es) * | 2019-02-13 | 2022-01-31 | Vanda Pharmaceuticals Inc | Metodo para mejorar el sue?o. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2176854A1 (en) * | 1995-06-07 | 1996-12-08 | Daniel J. Keavy | N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics |
| CN1152679C (zh) | 1996-12-10 | 2004-06-09 | 布里斯托尔-迈尔斯斯奎布公司 | 苯并二氧杂环戊烯、苯并呋喃、二氢苯并呋喃和苯并二噁烷类化合物褪黑激素能药剂 |
| CN1578664A (zh) | 2001-10-30 | 2005-02-09 | 诺瓦提斯公司 | 伊潘立酮和星状聚合物的贮库制剂 |
| GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| SI2806863T1 (sl) * | 2012-01-26 | 2017-12-29 | Vanda Pharmaceuticals Inc. | Zdravljenje motenj cirkadianega ritma |
| AU2013262631B2 (en) * | 2012-05-18 | 2016-02-04 | Vanda Pharmaceuticals Inc. | Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide |
-
2013
- 2013-05-17 AU AU2013262631A patent/AU2013262631B2/en active Active
- 2013-05-17 KR KR1020147033530A patent/KR20150005691A/ko not_active Withdrawn
- 2013-05-17 US US14/401,857 patent/US9212129B2/en active Active
- 2013-05-17 CA CA2872324A patent/CA2872324C/en active Active
- 2013-05-17 NZ NZ701515A patent/NZ701515A/en unknown
- 2013-05-17 KR KR1020187023795A patent/KR20180095737A/ko not_active Ceased
- 2013-05-17 BR BR112014028446A patent/BR112014028446A2/pt not_active Application Discontinuation
- 2013-05-17 EP EP13724708.6A patent/EP2855424B1/en active Active
- 2013-05-17 WO PCT/US2013/041573 patent/WO2013173707A1/en not_active Ceased
- 2013-05-17 KR KR1020177015054A patent/KR101891299B1/ko active Active
- 2013-05-17 RU RU2014151161A patent/RU2632889C2/ru active
- 2013-05-17 JP JP2015512886A patent/JP5959083B2/ja active Active
- 2013-05-17 MX MX2014014010A patent/MX2014014010A/es active IP Right Grant
- 2013-05-17 ES ES13724708.6T patent/ES2648987T3/es active Active
- 2013-05-17 CN CN201380025225.6A patent/CN104583178A/zh active Pending
- 2013-05-17 IN IN10691DEN2014 patent/IN2014DN10691A/en unknown
- 2013-05-17 CN CN201811055156.4A patent/CN108997160A/zh active Pending
-
2014
- 2014-11-03 IL IL235485A patent/IL235485A/en active IP Right Grant
- 2014-11-03 ZA ZA2014/08014A patent/ZA201408014B/en unknown
- 2014-11-18 CL CL2014003126A patent/CL2014003126A1/es unknown
- 2014-11-25 CO CO14259603A patent/CO7151504A2/es unknown
-
2015
- 2015-11-10 US US14/937,786 patent/US9617203B2/en active Active
-
2017
- 2017-03-02 US US15/447,946 patent/US9850199B2/en active Active
- 2017-12-08 US US15/836,099 patent/US10233142B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00127A (enExample) | ||
| HUE047977T2 (hu) | Bacillus Megaterium bioaktív készítmények és metabolitok | |
| AU2016202480A1 (en) | Seed-origin endophyte populations, compositions, and methods of use | |
| PH12019500176B1 (en) | Heterocyclic compounds and ther uses | |
| EP3060041A4 (en) | Prostacyclin compounds, compositions and methods of use thereof | |
| EP4450130A3 (en) | Formulations of enzalutamide | |
| MX2013008390A (es) | Preparacion de estructuras de metal-triazolato. | |
| GEP201706745B (en) | Forms of rifaximin and usage thereof | |
| PH12012501355A1 (en) | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | |
| MY172739A (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| MY187449A (en) | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl | |
| PH12013500500A1 (en) | Fused heteroaryls and their uses | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| IN2012MU03723A (enExample) | ||
| IN2014DN10691A (enExample) | ||
| IN2013MU00848A (enExample) | ||
| GEP201706626B (en) | Synthesis of (s)-nifuratel | |
| IN2014DN09450A (enExample) | ||
| EP3085701A4 (en) | N, n' substituted piperidinamine compounds, and preparation method and usage thereof | |
| HK40032142A (en) | Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor | |
| UA54879U (ru) | Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия | |
| PT2885399T (pt) | Composições bioativas e metabólitos de bacillus megaterium | |
| AU2017903222A0 (en) | Further improved uses of new formulations | |
| UA90039U (en) | Ethyl ester of 6-thioxo-3-(4-fluorophenyl)-7-cyano-1,3,4,6-2h-pyrido[1,2-a][1,3,5]triazine-9-carboxylic acid |